Effect of a High Protein Diet on the 24-hour Profile of Ghrelin, GH (Growth Hormone) and IGF-1 (Insulin-like Growth Factor-1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00108225 |
|
Recruitment Status :
Completed
First Posted : April 15, 2005
Last Update Posted : July 1, 2014
|
Sponsor:
VA Office of Research and Development
Information provided by (Responsible Party):
VA Office of Research and Development
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
In this study we tested the hypothesis that an increase in protein content of the diet will result in an increase in the 24-hour integrated circulating growth hormone (GH) and insulin-like growth factor-1 (IGF-1) concentrations and an increase in lean body mass in people with untreated type 2 diabetes.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diabetes Mellitus, Type 2 | Other: LoBag Diet - test phase Other: LoBAG Diet - control phase | Not Applicable |
Subjects with untreated type 2 diabetes were studied using a randomized crossover design. The study began with an initial two-week observation period. Subjects then were randomly assigned to one arm of the study for 5 weeks. The carbohydrate:protein:fat ratio for the control diet is 55:15:30 whereas for the test diet it is 40:30:30. Following a five-week washout period, subjects were assigned to the other arm of the study. All meals were provided by the SDTU. A six-day rotating meal plan has been devised. At the beginning and end of the 5-week diet period, the subject was admitted to the SDTU (Special Diagnostic and Treatment Unit), was provided with the meals appropriate for the test or control arm of the study, and had blood drawn at various times during a 24-hour period. In addition to measurement of GH and IGF-1, IGF-binding proteins 1 and 3, ghrelin, and body composition were determined.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 8 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | 2895 Effect of a High Protein Diet on the 24-hr Profile of Ghrelin, GH and IGF-1 |
| Study Start Date : | July 2004 |
| Actual Primary Completion Date : | December 2008 |
| Actual Study Completion Date : | May 2009 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Arm 1
30% carbohydrate, 30% protein, 40% fat
|
Other: LoBag Diet - test phase
A Low Biologically Available Glucose (LOBAG30), weight maintaining diet consisting of 30% carbohydrate, 30% protein, 40% fat will be provided to subjects for 5 weeks. |
|
Placebo Comparator: Arm 2
55% carbohydrate, 15% protein, 30% fat
|
Other: LoBAG Diet - control phase
A control, weight maintaining diet consisting of 55% carbohydrate, 15% protein, 30% fat will be provided to subjects for 5 weeks |
Primary Outcome Measures :
- IGF-1, GH, Body Composition [ Time Frame: 5 weeks ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 55 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- People ages 55 - 75 years old with type 2 diabetes, not receiving oral hypoglycemic agents or insulin.
- Fasting plasma glucose < 250 mg/dl (<14 mM) (tGHb < 14%).
Exclusion Criteria:
- Subjects will be screened for hematological abnormalities, liver disease, kidney disease, macroalbuminuria (>300 mg/24 hours), untreated thyroid disease, congestive heart failure, angina, life-threatening malignancies, proliferative retinopathy, diabetic neuropathy, peripheral vascular disease, serious psychological disorders, a body mass index > 35, and a fasting triglyceride of > 400 mg/dl.
- Presence of any of the above will be considered exclusion criteria.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00108225
Locations
| United States, Minnesota | |
| VA Medical Center, Minneapolis | |
| Minneapolis, Minnesota, United States, 55417 | |
Sponsors and Collaborators
VA Office of Research and Development
Investigators
| Principal Investigator: | Mary Gannon, PhD | Minneapolis Veterans Affairs Medical Center |
Publications of Results:
| Responsible Party: | VA Office of Research and Development |
| ClinicalTrials.gov Identifier: | NCT00108225 History of Changes |
| Other Study ID Numbers: |
03448-A |
| First Posted: | April 15, 2005 Key Record Dates |
| Last Update Posted: | July 1, 2014 |
| Last Verified: | June 2014 |
Keywords provided by VA Office of Research and Development:
|
Cholesterol Creatinine Clearance Diabetes Glycohemoglobin High Protein Diet |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Mecasermin Growth Substances Physiological Effects of Drugs |